Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Liabilities (2017 - 2025)

Cue Biopharma's Total Liabilities history spans 9 years, with the latest figure at $18.4 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 5.38% year-over-year to $18.4 million; the TTM value through Sep 2025 reached $18.4 million, down 5.38%, while the annual FY2024 figure was $14.7 million, 39.9% down from the prior year.
  • Total Liabilities for Q3 2025 was $18.4 million at Cue Biopharma, down from $22.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $27.2 million in Q2 2023 and bottomed at $14.7 million in Q4 2024.
  • The 5-year median for Total Liabilities is $22.5 million (2025), against an average of $21.6 million.
  • The largest annual shift saw Total Liabilities soared 120.91% in 2021 before it crashed 39.9% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $17.9 million in 2021, then soared by 42.95% to $25.6 million in 2022, then dropped by 4.52% to $24.4 million in 2023, then plummeted by 39.9% to $14.7 million in 2024, then grew by 25.22% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Total Liabilities are $18.4 million (Q3 2025), $22.5 million (Q2 2025), and $15.7 million (Q1 2025).